Pharmaceuticals

NOVARTIS AG

Salesforce

Conference Minutes

INFA

OpenAI

DXYZ

GOOG

GOOGL

GGLS

GGLL

ARR-C

<p>The following are the minutes of the FY26Q3 earnings call for <span class="security-tag" type="security-tag" counter_id="ST/US/CRM" name="Salesforce" trend="">$Salesforce(CRM.US)</span> compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article &#34;Salesforce: Is the AI Agent 'Delayed', and Has the SaaS Leader Become a Value Stock?&#34; 1. Review of Core Financial Information Guidance: The company is still expected to reaccelerate revenue growth within the next 12 to 18 months. Net new AOV growth: Net new AOV growth in the second half of FY26 is expected to exceed AOV growth in the second half...</p>

Informatica

Destiny Tech100

Haleon

Alphabet - C

Alphabet

IRSA Inversiones

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Armour Residential Reit

Gartner

Hasbro

ING Groep

ARMOUR RESIDENTIAL REIT INC 7.00% CUM RED PFD STK SER C

Salesforce (Minutes): The foundation of technology and sales has been laid, looking forward to the harvest period

JPMorgan Maintains Buy Rating on Novartis

Novartis Reaches Agreement with US Government to Lower Prices of Innovative Drugs

Novartis Reaches Drug Pricing Agreement with US Government and Other Pharma Companies

Novartis to Launch Future New Drugs at Comparable Prices in High-Income Countries

Novartis Expected to Receive Three Years of Tariff Exemptions

Novartis Launches Manufacturing Center Construction in North Carolina

Novartis to Invest $23 Billion Over Five Years to Expand US Operations

Pharmaceutical Companies Reach Agreement with US Government on Lowering Prescription Drug Prices

Novartis and Roche Near Deal on US Drug Prices

Novartis and Roche Near Deal in Drug Pricing Talks with White House

Novartis Chooses Salesforce Platform to Enhance Global Customer Engagement

U.S. Bank Securities Analyst Reiterates Buy Rating on Novartis

Tai kang Biotech's Biologic Similar Drug EG12014 Receives FDA CRL

Novartis AG Launches 700,000 Square Foot Manufacturing Center Construction in the US

Novartis and Relation Therapeutics Enter into $1.7 Billion Agreement to Develop New Targets for Atopic Diseases

Novartis' ianalumab significantly extends disease control time for patients with immune thrombocytopenia

Novartis Reports Kisqali® Effectiveness in Breast Cancer Patients

Novartis and Relation Therapeutics Reach $1.7 Billion Drug Target Deal

JPMorgan Raises Novartis' Rating and Price Target

Legal & General Group Plc Increased Its Stake in Novartis AG

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Novartis (NVS.US) 2024 Third Quarter Earnings Conference Call

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio